Calculators

401k Retirement Calculator Mortgage Calculator

New

Student Loan Calculator Auto Loan Calculator

Education

How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks TipRanks Community Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Smart Portfolio Expert Center TipRanksAI

TOOLS

Daily Analyst Ratings

STOCKS

ADVANCED RESEARCH

Invest Like a Pro with Unique Data & Simplifed ToolsTry Now

Dividend Center

Best Dividend Stocks

Popular

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

STSA

The FlySeven option delistings on June 21st

10M ago

HSC

MGI

PremiumThe Fly

Biotech Alert: Searches spiking for these stocks today

10M ago

CERS

HOOK

PremiumThe Fly

Biotech Alert: Searches spiking for these stocks today

10M ago

GRTX

HOOK

PremiumThe Fly

Biotech Alert: Searches spiking for these stocks today

10M ago

CFRX

MRKR

PremiumPre-Earnings

STSA Upcoming Earnings Report: What to Expect?

11M ago

STSA

Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

PremiumPress ReleasesSatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

11M ago

STSA

PremiumThe Fly

Satsuma Pharmaceuticals announces three abstracts accepted at AAN meeting

12M ago

STSA

PremiumPress Releases

Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

12M ago

STSA

PremiumThe Fly

Satsuma Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

12M ago

STSA

PremiumMarket News

Satsuma Skyrockets after Acquisition by Shin Nippon

1y ago

STSA

PremiumThe Fly

SNBL to acquire Satsuma Pharmaceuticals for 91c in cash per share

1y ago

STSA

PremiumPress Releases

SNBL to Acquire Satsuma Pharmaceuticals

1y ago

STSA

PremiumPress ReleasesSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

1y ago

STSA

PremiumThe Fly

Satsuma to submit STS101 NDA filing in Q1, seeking commercialization partner

1y ago

STSA

PremiumPress Releases

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

1y ago

STSA

PremiumPress Releases

Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

1y ago

STSA

PremiumMarket News

Satsuma Pharma Feels the Pain As Clinical Trial Results Disappoint

1y ago

STSA

PremiumPress Releases

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

2y ago

STSA

PremiumPress Releases

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

2y ago

STSA

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

PremiumPress ReleasesSatsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

2y ago

STSA

PremiumMarket News

Satsuma Posts Wider-Than-Feared Quarterly Loss

3y ago

STSA

STSA

Trending

Indices

Stocks

ETFs